RxDoctor Payments Data

Ankur Shah, DO

Clinical Cardiac Electrophysiology · Columbus, OHNPI 1013332857

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (39.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Medtronic at 51.1% of the total. Reporting peaked in 2020 at $20,050 and has fallen 57.8% since, to $8,459 in 2025.

$74,803in general payments, 2019–2025

Across 420 payments — averaging $178.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$38K
  • Boston Scientific$18K
  • Abbott$13K
  • Biosense Webster, Inc.$3K
  • Biotronik Inc.$465
  • AstraZeneca$323
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$3,1254%
  • Grants$29,39339%
  • Travel & lodging$22,26530%
  • Food & beverage$19,30126%
  • Education$7191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,803 in reported general payments places this provider in the 85th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

See all clinical cardiac electrophysiology providers in Ohio

Medicare billing

Part B allowed, 2024
$258,682
Medicare patients
1,725
Services billed
3,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$229,627
XareltoRivaroxaban185$197,012
Flecainide Acetate225$7,745
Dofetilide26$7,086
Metoprolol Succinate261$2,975
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$2,254
Propafenone Hcl ErPropafenone Hcl13$1,765
Amiodarone Hcl88$1,076
SotalolSotalol Hcl27$753
Pantoprazole Sodium48$311
Warfarin Sodium48$307
Metoprolol Tartrate53$302
Atorvastatin Calcium15$177
Losartan Potassium15$130
Carvedilol19$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$229,627210 claims
Johnson & JohnsonXarelto$140$197,012185 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

Other clinical cardiac electrophysiology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →